Compare Boston Scientific Corporation (BSX) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Genuine Parts Company — how do they compare? Boston Scientific Corporation trades at $42.51 (market cap $66.37B), while Genuine Parts Company trades at $122.5 (market cap $16.81B). The key difference: Boston Scientific Corporation is far larger — about 3.9× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.48% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GPC | |
|---|---|---|
Market Cap | $66.37B | $16.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $149.26 |
52-Week Low | $42.63 | $92.47 |
Enterprise Value | $75.94B | $23.03B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
GPC trades at $123.52, down 1.67% over the past day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results expected on July 21, 2026. Revenue growth remains modest at $24.3B in 2025, though net income margins have compressed significantly to 0.24%. Analyst sentiment is mixed with a consensus price target of $133.00, representing a 7.7% upside from current levels.
GPC offers potential for moderate upside based on analyst targets and dividend stability, but faces headwinds from declining profitability margins and recent earnings misses. The stock's high P/E ratio of 280.73 suggests premium valuation despite weak earnings growth, while strong cash flow generation and Dividend King status provide some downside protection. Key risks include margin pressure and competitive threats in the automotive parts distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
